Controversial Kratom Appeared to Cause Severe Ulcerative Colitis Flare
(MedPage Today) -- VANCOUVER, British Columbia -- In a case believed to be the first such report in medical literature, researchers said here they have documented how use of the controversial substance kratom (Mitragyna speciosa) appeared to... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 24, 2023 Category: American Health Source Type: news
FDA Approves Subcutaneous Infliximab for IBD FDA Approves Subcutaneous Infliximab for IBD
The approval provides an alternative administration option for delivering the drug to patients with moderately to severely active ulcerative colitis or Crohn ' s disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 23, 2023 Category: Consumer Health News Tags: Gastroenterology News Alert Source Type: news
Roche Secures Promising Bowel Disease Therapy —Which Could Help Treat Crohn’s—In $7.1 Billion Telavant Deal
The Swiss pharma giant said it will begin late-stage trials on the experimental antibody therapy “as soon as possible” to help bring it to patients suffering from inflammatory bowel disease. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 23, 2023 Category: Pharmaceuticals Authors: Robert Hart, Forbes Staff Tags: Business /business Innovation /innovation Healthcare /healthcare Breaking breaking-news topline Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant
Roche will gain the rights to develop, manufacture and commercialise RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and potentially multiple other diseasesRVT-3101 is a Phase 3-ready antibody with first-in-class and best-in-disease potential, a novel mode of action and strong Phase 2b data in ulcerative colitisRoche will also obtain an option to enter into a global collaboration with Pfizer on a next-generation p40/TL1A directed bispecific antibody, currently in Phase 1Under the terms of the agreement, Roche will pay a purchase price of US$ 7.1 billion upfront and a near-term milestone payment...
Source: Roche Investor Update - October 23, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant
Roche will gain the rights to develop, manufacture and commercialise RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and potentially multiple other diseasesRVT-3101 is a Phase 3-ready antibody with first-in-class and best-in-disease potential, a novel mode of action and strong Phase 2b data in ulcerative colitisRoche will also obtain an option to enter into a global collaboration with Pfizer on a next-generation p40/TL1A directed bispecific antibody, currently in Phase 1Under the terms of the agreement, Roche will pay a purchase price of US$ 7.1 billion upfront and a near-term milestone payment...
Source: Roche Media News - October 23, 2023 Category: Pharmaceuticals Source Type: news
FDA Approves Zymfentra (infliximab-dyyb) Subcutaneous Formulation for the Treatment of People With Inflammatory Bowel Disease
JERSEY CITY, N.J.--(BUSINESS WIRE) October 23, 2023 --Today, Celltrion USA announced that the U.S. Food and Drug Administration (FDA) has approved Zymfentra (infliximab-dyyb) for maintenance therapy in adults with moderately to severely active... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 23, 2023 Category: Drugs & Pharmacology Source Type: news
Transcutaneous Auricular Vagus Nerve Stimulation Beneficial in Pediatric IBD
FRIDAY, Oct. 20, 2023 -- For pediatric patients with mild-to-moderate inflammatory bowel disease, transcutaneous auricular vagus nerve stimulation (ta-VNS) attenuates signs and symptoms of disease, according to a study published online Oct. 18 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 20, 2023 Category: Pharmaceuticals Source Type: news
FDA Approves Velsipity for Moderate-to-Severe Ulcerative Colitis in Adults
TUESDAY, Oct. 17, 2023 -- The U.S. Food and Drug Administration approved Velsipity (etrasimod) for adults with moderately to severely active ulcerative colitis (UC).
The approval was based on results from the ELEVATE UC phase 3 registrational... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 17, 2023 Category: General Medicine Source Type: news
FDA Approves Velsipity (etrasimod) for Adults with Moderately to Severely Active Ulcerative Colitis (UC)
NEW YORK--(BUSINESS WIRE) October 13, 2023 -- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Velsipity™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 13, 2023 Category: Drugs & Pharmacology Source Type: news
FDA Approves New Drug for Ulcerative Colitis FDA Approves New Drug for Ulcerative Colitis
Etrasimod is the second oral sphingosine-1-phosphate (S1P) receptor approved in the US for treating moderate to severe active ulcerative colitis in adults.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - October 13, 2023 Category: Drugs & Pharmacology Tags: Gastroenterology News Alert Source Type: news
Pfizer Wins FDA Approval for New Ulcerative Colitis Pill
The treatment, to be marketed at Velsipity, is one of a number of new products that Pfizer expects to bring in a combined $20 billion in potential annual revenue by 2030.#velsipity #pfizer (Source: Reuters: Health)
Source: Reuters: Health - October 13, 2023 Category: Consumer Health News Source Type: news
New Oral Drug Approved for Ulcerative Colitis in Adults
(MedPage Today) -- The FDA approved oral etrasimod (Velsipity) on Friday for treating moderately to severely active ulcerative colitis (UC) in adults, drugmaker Pfizer announced.
Approval of the selective sphingosine-1-phosphate (S1P) receptor... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 13, 2023 Category: American Health Source Type: news
COVID Might Raise Odds for Immune Disorders Like Crohn's, Alopecia
TUESDAY, Oct. 10, 2023 -- In rare cases, some patients may develop an autoimmune disease following a bout of COVID, Korean researchers report.
Conditions such as alopecia (hair loss), psoriasis, vitiligo (white skin patches), vasculitis... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 10, 2023 Category: General Medicine Source Type: news
Teva Pharma Hooks Sanofi In $1.5 Billion Inflammation Deal. But Shares Tumble
Teva stock yo-yoed and then tumbled Wednesday after the company announced it would partner with French pharma giant Sanofi (SNY) to develop an inflammatory bowel disease treatment. The drug belongs to the emerging TL1A class and could eventually rival experimental treatments from Roivant Sciences…#roivantsciences #pfe #merck #prometheusbio #teva #sanofi #tevapharmaceutical #crohn #prometheus #paulhudson (Source: Reuters: Health)
Source: Reuters: Health - October 4, 2023 Category: Consumer Health News Source Type: news
Inflammatory Bowel Disease Tied to Higher Risk for Gout
TUESDAY, Oct. 3, 2023 -- Inflammatory bowel disease (IBD) is strongly associated with gout, according to a study published online Sept. 1 in JGH Open.
Osama Hamid, M.B.B.S., from the Cleveland Clinic, and colleagues investigated the association... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 3, 2023 Category: Pharmaceuticals Source Type: news
